Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Cervical cancer
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Results 1-25 of 91 for your search:
Start Over
Intensity Modulated Radiation Therapy in Treating Patients with Gynecologic Cancers
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 110808, NCI-2012-02858, NCT01554397
Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0724/GOG-0724, NCI-2011-01973, CDR0000654709, GOG-0724, RTOG-0724, NCT00980954
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: GOG-0263, NCI-2011-02037, CDR0000670125, NCT01101451
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: ANZGOG-0902/GOG-0274/RTOG-1174, NCI-2011-02978, ANZGOG-0902, CDR0000706698, GOG-0274, RTOG-1174, ANZGOG-0902-GOG-0274, NCT01414608
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Epidural Anesthesia within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: UW14030, NCI-2015-00395, NCT02423876
Negative Pressure Wound Therapy in Caring for Women After Abdominal Surgery
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 15-309, NCI-2016-00514, NCT02682316
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: HPV-004, NCI-2015-00497, NCT02172911
T-cell Receptor Gene Therapy Targeting HPV-16 E6 in Treating Patients with Metastatic, Recurrent, or Refractory HPV-Related Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 66
Trial IDs: 15-C-0005, NCI-2014-02319, 1407-1331, 337514, P141607, RD-14-VII-09, RD-14-VIII-09, NCT02280811
A Study to Investigate the Safety and Efficacy of Nivolumab, and Nivolumab in Combination With Ipilimumab, in Virus-associated Tumors (CheckMate358)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-358, NCI-2015-01356, 2015-000230-29, NCT02488759
ATR Kinase Inhibitor VX-970 and Topotecan Hydrochloride in Treating Patients with Previously Treated Lung, Ovarian, Cervical, or Neuroendocrine Cancers
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0150, NCI-2015-01398, 346215, P142115, NCT02487095
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348
High Dose Rate Brachytherapy in Treating Patients with Endometrial, Cervical, Lung, Breast, or Prostate Cancer
Status: Active
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 18 to 90
Trial IDs: 09-C-0100, NCI-2013-01448, 090100, 302844, P08407, NCT00924027
Vaccine Therapy in Treating Patients with Persistent or Recurrent Cervical Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GOG-0265, NCI-2011-02671, CDR0000691288, NCT01266460
Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin after Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Refractory Human Papilloma Virus-Associated Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0116, NCI-2013-01524, 120116, 327146, P11943, NCT01585428
Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5C-11-2, NCI-2012-01378, HS-11-00547, NCT01676818
Psychosexual Intervention in Patients With Stage I-III Gynecologic Cancer
Status: Active
Phase: Phase II
Type: Supportive care
Age: 21 to 80
Trial IDs: OSU-10077, NCI-2012-01341, 2010C0088, NCT01764802
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients with Metastatic, Persistent, or Recurrent Cervical Cancer
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-334, NCI-2013-02357, NCT01958112
Image Guided Hypofractionated Radiation Therapy in Treating Patients with Stage IB-IVB Cervical Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: STU 082013-064, NCI-2015-01672, NCT02045433
Nivolumab in Treating Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY002, NCI-2014-02021, PNRG-GY002_A01PAMDREVW01, NCT02257528
Start Over